Dianthus Therapeutics Inc traded at $90.20 this Wednesday July 1st, decreasing $7.28 or 7.47 percent since the previous trading session. Looking back, over the last four weeks, Dianthus Therapeutics lost 10.58 percent. Over the last 12 months, its price rose by 390.75 percent. Looking ahead, we forecast Dianthus Therapeutics Inc to be priced at 93.37 by the end of this quarter and at 87.66 in one year, according to Trading Economics global macro models projections and analysts expectations.
Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to advancing antibody complement therapeutics to treat severe autoimmune diseases. The Company is dedicated to designing and delivering monoclonal antibodies with improved selectivity and potency. The Company has initiated a Phase 2 trial of DNTH103, a potential active C1s inhibitor, in generalized Myasthenia Gravis and plans to initiate additional Phase 2 trials in other neuromuscular indications, including Multifocal Motor Neuropathy and Chronic Inflammatory Demyelinating Polyneuropathy. Its product candidate, DNTH103, is a clinical-stage, highly potent, highly selective and fully human monoclonal immunoglobulin G4 with picomolar binding affinity that is designed to selectively bind only to the active form of the C1s complement protein. DNTH103 is engineered with YTE half-life extension technology, a specific three amino acid change in the Fc domain, and has a pharmacokinetic (PK) profile.